Finalising the administration of co-SSPedi, a dyad approach to symptom screening for paediatric patients receiving cancer treatments.

paediatrics supportive care symptoms and symptom management

Journal

BMJ supportive & palliative care
ISSN: 2045-4368
Titre abrégé: BMJ Support Palliat Care
Pays: England
ID NLM: 101565123

Informations de publication

Date de publication:
07 Dec 2023
Historique:
received: 06 05 2021
accepted: 05 08 2021
pubmed: 25 9 2021
medline: 25 9 2021
entrez: 24 9 2021
Statut: epublish

Résumé

Symptom Screening in Pediatrics Tool (SSPedi) is a validated self-report symptom screening tool for patients with cancer 8-18 years of age. Co-SSPedi is a novel dyad approach in which both child and parent complete SSPedi together. The objective was to finalise the approach to co-SSPedi administration with instruction that is easy to understand, resulting in dyads completing co-SSPedi correctly. We enrolled child and parent dyads, who understood English and where children (4-18 years) had cancer or were hematopoietic stem cell transplantation recipients. We provided each dyad with instruction on how to complete co-SSPedi together. Mixed methods were used to determine how easy or hard the instruction was to understand. Two raters adjudicated if co-SSPedi was completed correctly. Dyads were enrolled in cohorts of 12 evenly divided by age (4-7, 8-10, 11-14 and 15-18 years). We enrolled 5 cohorts of 12 dyads, resulting in 60 dyads. Following verbal instruction provided in the first cohort, we identified the need for written instruction emphasising children should wait for parent response prior to entering scores. The instruction was iteratively refined based on qualitative feedback until the fifth cohort, where all 12 dyads found the instruction easy to understand and completed co-SSPedi correctly. We developed a standard approach to dyad symptom screening named co-SSPedi with instruction that is easy to understand, resulting in correct co-SSPedi completion. Future efforts should focus on co-SSPedi validation and understanding how co-SSPedi scores compare to self- or proxy-reported symptom reporting.

Identifiants

pubmed: 34556545
pii: bmjspcare-2021-003169
doi: 10.1136/bmjspcare-2021-003169
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e469-e475

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Deborah Tomlinson (D)

Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada deborah.tomlinson@sickkids.ca.

Tal Schechter (T)

Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.

Mark Mairs (M)

Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.

Robyn Loves (R)

Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.

Daniel Herman (D)

Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.

Emily Hopkins (E)

Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.

L Lee Dupuis (LL)

Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

Lillian Sung (L)

Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.

Classifications MeSH